These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 9275009)
1. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. Morimoto Y; Nishikawa K; Ohashi M Life Sci; 1997; 61(8):795-803. PubMed ID: 9275009 [TBL] [Abstract][Full Text] [Related]
2. Effect of a matrix metalloproteinase inhibitor on host resistance against Listeria monocytogenes infection. Yamada K; Yoshino K; Sekikawa K; Madarame H; Yagita H; Nakane A FEMS Immunol Med Microbiol; 2000 Nov; 29(3):187-94. PubMed ID: 11064265 [TBL] [Abstract][Full Text] [Related]
3. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation. Hattori K; Hirano T; Oshimi K; Yagita H; Okumura K Leuk Lymphoma; 2000 Aug; 38(5-6):553-61. PubMed ID: 10953977 [TBL] [Abstract][Full Text] [Related]
4. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Lozonschi L; Sunamura M; Kobari M; Egawa S; Ding L; Matsuno S Cancer Res; 1999 Mar; 59(6):1252-8. PubMed ID: 10096556 [TBL] [Abstract][Full Text] [Related]
5. Effect of TNF-alpha--converting enzyme inhibitor on insulin resistance in fructose-fed rats. Togashi N; Ura N; Higashiura K; Murakami H; Shimamoto K Hypertension; 2002 Feb; 39(2 Pt 2):578-80. PubMed ID: 11882611 [TBL] [Abstract][Full Text] [Related]
8. A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation. Hattori K; Hirano T; Ushiyama C; Miyajima H; Yamakawa N; Ikeda S; Yoshino K; Tateno M; Oshimi K; Kayagaki N; Yagita H; Okumura K Bone Marrow Transplant; 1999 Jun; 23(12):1283-9. PubMed ID: 10414917 [TBL] [Abstract][Full Text] [Related]
9. Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats. Murase K; Odaka H; Suzuki M; Tayuki N; Ikeda H Diabetologia; 1998 Mar; 41(3):257-64. PubMed ID: 9541164 [TBL] [Abstract][Full Text] [Related]
10. Hepatic insulin resistance in KKA(y) mice and its amelioration by pioglitazone do not involve alterations in phospholipase C activity. Bleasdale JE; Swanson ML Biochim Biophys Acta; 1993 Jun; 1181(3):240-8. PubMed ID: 8391325 [TBL] [Abstract][Full Text] [Related]
11. A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice. Shibasaki M; Takahashi K; Itou T; Bujo H; Saito Y Biochem Biophys Res Commun; 2003 Sep; 309(2):419-24. PubMed ID: 12951066 [TBL] [Abstract][Full Text] [Related]
12. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Hofmann CA; Edwards CW; Hillman RM; Colca JR Endocrinology; 1992 Feb; 130(2):735-40. PubMed ID: 1733721 [TBL] [Abstract][Full Text] [Related]
13. Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice. Weinstock RS; Murray FT; Diani A; Sangani GA; Wachowski MB; Messina JL Pharmacology; 1997 Apr; 54(4):169-78. PubMed ID: 9211562 [TBL] [Abstract][Full Text] [Related]
14. Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Tang Y; Osawa H; Onuma H; Nishimiya T; Ochi M; Makino H Diabetes; 1999 Sep; 48(9):1830-5. PubMed ID: 10480615 [TBL] [Abstract][Full Text] [Related]
15. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation. Hattori K; Hirano T; Miyajima H; Yamakawa N; Ikeda S; Yoshino K; Tateno M; Oshimi K; Kayagaki N; Yagita H; Okumura K Br J Haematol; 1999 Apr; 105(1):303-12. PubMed ID: 10233398 [TBL] [Abstract][Full Text] [Related]
16. Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. Saha AK; Kurowski TG; Colca JR; Ruderman NB Am J Physiol; 1994 Jul; 267(1 Pt 1):E95-101. PubMed ID: 8048519 [TBL] [Abstract][Full Text] [Related]
17. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525 [TBL] [Abstract][Full Text] [Related]
18. TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone. Miles PD; Romeo OM; Higo K; Cohen A; Rafaat K; Olefsky JM Diabetes; 1997 Nov; 46(11):1678-83. PubMed ID: 9356012 [TBL] [Abstract][Full Text] [Related]
19. A selective inhibitor of matrix metalloproteinases inhibits the migration of isolated osteoclasts by increasing the life span of podosomes. Goto T; Maeda H; Tanaka T J Bone Miner Metab; 2002; 20(2):98-105. PubMed ID: 11862531 [TBL] [Abstract][Full Text] [Related]